Axsome Therapeutics (AXSM) Competitors $86.70 -1.27 (-1.44%) (As of 12/27/2024 05:30 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends AXSM vs. UTHR, RPRX, VTRS, SMMT, GMAB, RDY, BMRN, INSM, CTLT, and SRPTShould you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include United Therapeutics (UTHR), Royalty Pharma (RPRX), Viatris (VTRS), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), BioMarin Pharmaceutical (BMRN), Insmed (INSM), Catalent (CTLT), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry. Axsome Therapeutics vs. United Therapeutics Royalty Pharma Viatris Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories BioMarin Pharmaceutical Insmed Catalent Sarepta Therapeutics Axsome Therapeutics (NASDAQ:AXSM) and United Therapeutics (NASDAQ:UTHR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment, community ranking and earnings. Which has more volatility and risk, AXSM or UTHR? Axsome Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Does the media favor AXSM or UTHR? In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 9 articles in the media. Axsome Therapeutics' average media sentiment score of 1.09 beat United Therapeutics' score of 0.94 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive United Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, AXSM or UTHR? United Therapeutics has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAxsome Therapeutics$338.46M12.41-$239.24M-$6.53-13.28United Therapeutics$2.76B5.83$984.80M$22.7715.81 Is AXSM or UTHR more profitable? United Therapeutics has a net margin of 40.31% compared to Axsome Therapeutics' net margin of -91.87%. United Therapeutics' return on equity of 19.22% beat Axsome Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Axsome Therapeutics-91.87% -158.36% -37.46% United Therapeutics 40.31%19.22%16.15% Do institutionals and insiders hold more shares of AXSM or UTHR? 81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 22.4% of Axsome Therapeutics shares are held by company insiders. Comparatively, 11.9% of United Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate AXSM or UTHR? Axsome Therapeutics currently has a consensus target price of $125.93, indicating a potential upside of 45.25%. United Therapeutics has a consensus target price of $370.86, indicating a potential upside of 3.03%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Axsome Therapeutics is more favorable than United Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Axsome Therapeutics 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00United Therapeutics 1 Sell rating(s) 2 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.73 Does the MarketBeat Community prefer AXSM or UTHR? United Therapeutics received 146 more outperform votes than Axsome Therapeutics when rated by MarketBeat users. However, 69.10% of users gave Axsome Therapeutics an outperform vote while only 62.34% of users gave United Therapeutics an outperform vote. CompanyUnderperformOutperformAxsome TherapeuticsOutperform Votes44569.10% Underperform Votes19930.90% United TherapeuticsOutperform Votes59162.34% Underperform Votes35737.66% SummaryUnited Therapeutics beats Axsome Therapeutics on 9 of the 17 factors compared between the two stocks. Ad DarwinHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AXSM vs. The Competition Export to ExcelMetricAxsome TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.20B$6.64B$5.20B$9.13BDividend YieldN/A2.97%5.11%4.29%P/E Ratio-13.2810.6587.1517.18Price / Sales12.41204.681,117.35125.21Price / CashN/A57.1543.2337.87Price / Book21.465.184.855.01Net Income-$239.24M$150.75M$119.99M$225.06M7 Day Performance-4.44%3.64%2.76%5.06%1 Month Performance-13.00%-4.52%16.08%3.33%1 Year Performance8.89%6.13%29.53%17.72% Axsome Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AXSMAxsome Therapeutics4.8168 of 5 stars$86.70-1.4%$125.93+45.2%+3.7%$4.20B$338.46M-13.28589Short Interest ↓Positive NewsUTHRUnited Therapeutics4.4391 of 5 stars$362.31+0.8%$370.86+2.4%+67.5%$16.18B$2.76B15.911,168Insider TradeRPRXRoyalty Pharma4.8536 of 5 stars$25.22+1.2%$41.67+65.2%-8.8%$14.86B$2.27B13.0780Analyst UpgradeVTRSViatris1.3221 of 5 stars$12.44-0.6%$13.67+9.9%+15.9%$14.85B$15.05B-16.8138,000SMMTSummit Therapeutics2.2896 of 5 stars$18.57+3.9%$33.33+79.5%+559.8%$13.69B$700,000.00-66.32105GMABGenmab A/S4.1459 of 5 stars$20.59+1.4%$45.20+119.5%-33.8%$13.63B$19.84B19.992,204Positive NewsRDYDr. Reddy's Laboratories1.0469 of 5 stars$15.43+0.4%$17.00+10.2%+16.3%$12.88B$299.87B24.6527,048BMRNBioMarin Pharmaceutical4.9986 of 5 stars$66.26+0.9%$94.20+42.2%-31.7%$12.63B$2.75B39.683,401Short Interest ↓Positive NewsINSMInsmed3.1249 of 5 stars$69.92-0.7%$83.67+19.7%+120.0%$12.51B$342.96M-12.60373CTLTCatalent2.2429 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.42B-28.0916,900Analyst ForecastSRPTSarepta Therapeutics4.8564 of 5 stars$119.41+0.4%$178.71+49.7%+25.5%$11.41B$1.64B95.531,314 Related Companies and Tools Related Companies UTHR Alternatives RPRX Alternatives VTRS Alternatives SMMT Alternatives GMAB Alternatives RDY Alternatives BMRN Alternatives INSM Alternatives CTLT Alternatives SRPT Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AXSM) was last updated on 12/28/2024 by MarketBeat.com Staff From Our PartnersIs Jeff Bezos Crowning the Next Nvidia?It doesn't matter what you think about AI... Because Jeff Bezos's massive load-up on one tiny tech company ...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Elon’s Dec. 31st Surprise “Super-IPO”?There’s a little-known backdoor way to play Elon’s “Super-IPO”… With as little as $50. Paradigm Press | SponsoredFastest Way To Build Wealth From Trump Stock MELT UPDonald Trump is about to ignite the biggest… and fastest… stock market boom in American history. He will be...Banyan Hill Publishing | SponsoredMy meeting with TrumpThe investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
